Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick presented at the Pain Therapeutics Summit Europe in Amsterdam on May 7-8, 2026.

Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick presented at the Pain Therapeutics Summit Europe in Amsterdam on May 7-8, 2026. Her May 7 talk, "Chemical Control, Clinical Confidence: Rethinking Opioids," described molecularly engineered opioid approaches and highlighted Ensysce platforms TAAP14 and MPARAE aimed at reducing misuse and overdose risk. She also joined a panel on developing safer analgesics without sacrificing efficacy.

Argus May 8 session

-5.35% close to close Open Argus

Details

News Market Reaction – ENSC

On May 8, the day this news came out, ENSC closed 5.35% below the previous close.

Data tracked by StockTitan Argus for the May 8 session.

Market Context

On May 8, the day this news came out, the stock closed 5.3% below the previous close. A negative rea...

Analysis

On May 8, the day this news came out, the stock closed 5.3% below the previous close. A negative reaction despite the exposure-focused nature of this announcement fits a pattern where positive updates sometimes coincided with selling, as seen after several recent clinical and communication milestones. The stock previously sat 86.55% below its 52-week high at $0.37 before this news, and an effective resale registration for 20,335,491 shares may reinforce dilution and overhang concerns even though the company does not receive proceeds from holder resales.

Historical Context

5 past events · Latest: Apr 16

5 events

1. Apr 16

   Clinical trial progress

   24h Move

   -4.7%

   IRB approval to start final part of PF614-MPAR-102 overdose-protection study.

2. Apr 07

   Financing tranche

   24h Move

   +3.0%

   Second $2.0M convertible preferred tranche to fund pain programs and operations.

3. Mar 30

   Earnings and pipeline

   24h Move

   +4.8%

   FY2025 results with PF614 Phase 3 start and PF614-MPAR under Breakthrough status.

4. Mar 04

   Investor outreach AMA

   24h Move

   -1.0%

   Live AMA discussing PF614 strategy, capital discipline, and regulatory risk.

5. Mar 03

   Clinical publication

   24h Move

   -15.0%

   First peer-reviewed Phase 1 MPAR data showing oral overdose protection profile.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

prodrug, analgesic, central nervous system, plasma levels, +2 more

6 terms

prodrug medical

"PF614-MPAR, an oxycodone prodrug using MPAR® technology that limits oral overdose"

A prodrug is an inactive or less-active compound that is designed to be converted into an active drug inside the body, like a packaged meal that needs heating before it's ready to eat. For investors, prodrugs matter because this design can improve how a medicine is absorbed, reduce side effects, extend patent protection, or enable new dosing forms — all factors that can affect a drug's regulatory path, marketability, and commercial value.

analgesic medical

"advancements in analgesic care, including novel therapeutic candidates in development"

An analgesic is a medication that reduces or eliminates pain without putting a person to sleep, covering common over-the-counter remedies through stronger prescription drugs. For investors, analgesics matter because their safety profile, regulatory approvals, patent protection and broad or limited use determine sales potential, liability exposure and long-term profits—think of them as either everyday household staples or specialized tools that drive revenue and risk.

central nervous system medical

"next-generation pain and central nervous system therapeutics engineered to minimize"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

plasma levels medical

"creating a ceiling on drug plasma levels when excessive doses are taken"

Plasma levels are the concentration of a drug or biological molecule measured in the liquid portion of the blood. Investors watch these numbers because they indicate how much of a drug reaches the body, how long it stays at effective doses, and whether levels are safe; like measuring fuel in a tank to judge how far a car can go, plasma levels help predict dosing, side effects, regulatory approval chances, and commercial potential.

overdose protection medical

"PF614-MPAR, which holds FDA Breakthrough Therapy designation for overdose protection"

Overdose protection is a safety feature built into a drug, delivery device, or dispensing system that reduces the chance a person will take a harmful, excessive amount. Examples include formulations that release medicine slowly, built-in dose limits, or pairing with an emergency antidote—like a speed governor on a car that prevents going too fast. For investors, these features matter because they influence regulatory approval, legal risk, patient acceptance, and the commercial value of a product.

Breakthrough Therapy regulatory

"PF614-MPAR, which holds FDA Breakthrough Therapy designation and has NIDA-supported"

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~

SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, announced that CEO, Dr. Lynn Kirkpatrick, presented as an invited speaker and was featured on a panel at the first Pain Therapeutics Summit Europe held in Amsterdam May 7-8, 2026.

This meeting gathered experts from around the world to discuss latest advancements in analgesic care, including novel therapeutic candidates in development. Dr. Kirkpatrick's presentation on May 7th, titled "Chemical Control, Clinical Confidence: Rethinking Opioids," outlined a paradigm shift in opioid development-moving beyond traditional formulations to chemically engineered drugs with built-in safety controls.

Her presentation focused on redefining the opioid benefit-risk equation through molecular design, while addressing the persistent gap between analgesic efficacy and safety. Dr. Kirkpatrick highlighted Ensysce's proprietary platforms:

• TAAP^™ (Trypsin-Activated Abuse Protection): A unique prodrug platform designed to improve safety and reduce non-oral routes of misuse.

• MPAR^® (Multi-Pill Abuse Resistance): A breakthrough technology engineered to provide overdose protection by creating a ceiling on drug plasma levels when excessive doses are taken.

"Opioids have always forced a tradeoff between efficacy and safety," said Dr. Kirkpatrick. "Our approach is fundamentally different. By embedding control directly into the drug itself, we believe we can preserve the analgesic power physicians rely on and patients need, while actively reducing the risks that have defined this class for decades."

In addition to her presentation, Dr. Kirkpatrick participated in a panel of leading experts in the analgesic space to discuss "Safer Analgesics Without Losing Efficacy". The panel discussed key developments in the field that may lead to more effective pain products with better safety profiles. During the session, Dr. Kirkpatrick and the other experts discussed their clinical programs more fully and answered additional questions from the audience.

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP^™) and Multi-Pill Abuse Resistance (MPAR^®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ensysce (ENSC) CEO present at the Pain Therapeutics Summit Europe on May 7, 2026?

Dr. Lynn Kirkpatrick presented on chemically engineered opioids with built-in safety controls, focusing on TAAP14 and MPARAE. According to the company, the talk framed a paradigm shift toward prodrug and abuse-resistant designs intended to separate analgesic efficacy from overdose risk.

What are TAAP14 and MPARAE described by Ensysce (ENSC) at the Amsterdam symposium?

TAAP14 is a trypsin-activated prodrug platform; MPARAE is a multi-pill abuse resistance technology. According to the company, TAAP14 targets non-oral misuse reduction and MPARAE aims to limit plasma levels if excessive doses are taken.

When and where did Ensysce (ENSC) discuss its clinical pain programs in 2026?

Ensysce discussed its programs at the Pain Therapeutics Summit Europe in Amsterdam on May 7-8, 2026. According to the company, the CEO and panelists reviewed clinical development approaches and answered audience questions about safer analgesic candidates.

How did Ensysce (ENSC) describe the goal of its opioid design strategy?

The company described embedding safety controls into molecule design to preserve analgesia while reducing misuse and overdose potential. According to the company, this strategy focuses on molecular features and delivery characteristics that alter abuse and overdose pharmacology.

Did Ensysce (ENSC) participate in panel discussions at the Pain Therapeutics Summit Europe?

Yes. Dr. Lynn Kirkpatrick served on a panel titled "Safer Analgesics Without Losing Efficacy." According to the company, the panel exchanged updates on clinical programs and debated how to improve safety profiles without sacrificing therapeutic benefit.

What investor-relevant details did Ensysce (ENSC) provide at the Amsterdam meeting?

The company highlighted its proprietary platforms TAAP14 and MPARAE and their intended safety mechanisms. According to the company, presenters discussed how these technologies could influence clinical development pathways for opioid therapeutics.